

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
12 May 2022 (12.05.2022)



(10) International Publication Number
WO 2022/096604 A1

(51) International Patent Classification:

A61K 47/68 (2017.01) *A61P 35/00* (2006.01)

A61K 39/395 (2006.01) *C07K 16/28* (2006.01)

(21) International Application Number:

PCT/EP2021/080688

(22) International Filing Date:

04 November 2021 (04.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20205794.9 04 November 2020 (04.11.2020) EP

(71) Applicant: **HEIDELBERG PHARMA RESEARCH GMBH** [—/DE]; Gregor-Mendel-Straße 22, 68526 Ladenburg (DE).

(72) Inventors: **KULKE, Michael**; c/o, Heidelberg Pharma Research GmbH, Gregor-Mendel-Str. 22, 68526 Ladenburg (DE). **HECHLER, Torsten**; c/o, Heidelberg Pharma Research GmbH, Gregor-Mendel-Str. 22, 68526 Ladenburg (DE). **PAHL, Andreas**; c/o, Heidelberg Pharma Research GmbH, Gregor-Mendel-Str. 22, 68526 Ladenburg (DE). **MÜLLER, Christoph**; c/o, Heidelberg Pharma Research GmbH, Gregor-Mendel-Str. 22, 68526 Ladenburg (DE). **WERNER-SIMON, Susanne**; c/o, Heidelberg Pharma Research GmbH, Gregor-Mendel-Str. 22, 68526 Ladenburg (DE).

(74) Agent: **MICHALSKI HÜTTERMANN & PARTNER PATENTANWÄLTE MBB**; Speditionstraße 21, 40221 Düsseldorf (DE).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))



WO 2022/096604 A1

(54) Title: COMPOSITION COMPRISING A COMBINATION OF IMMUNE CHECKPOINT INHIBITOR AND ANTIBODY-AM-ATOXIN CONJUGATE FOR USE IN CANCER THERAPY

(57) Abstract: The present application relates to a composition comprising (a) at least one immune checkpoint inhibitor and (b) at least one conjugate, wherein said conjugate is comprising (i) a target binding moiety, (ii) at least one amatoxin, and (iii) optionally at least one linker connecting said target binding moiety with said at least one amatoxin. The present application further relates to said composition for use in treating a patient having a cancer, and to a pharmaceutical formulation comprising said composition and additional excipients, as well as to methods of producing and using said composition.